I read an interesting article recently on large-scale genome/cancer projects geared towards driving therapeutic discovery through “omics” based research.
Below is an excerpt of the article from Drug Discovery News.
Oncology researchers looking for new and better ways to treat cancer recently got what may be some of their best early ‘omics news since the Human Genome Project published initial results in 2000, with the announcement this summer that the largest study correlating genetics with cancer treatments released its first results.
The cross-Atlantic collaboration, dubbed the Genomics of Drug Sensitivity in Cancer project, is driven primarily by the U.S.-based Massachusetts General Hospital Cancer Center and the U.K-based Wellcome Trust Sanger Institute. In mid-July, the researchers described their initial data set regarding the responses of 350 cancer samples to 18 anticancer therapeutics, publishing the information for free on the Genomics of Drug Sensitivity in Cancer website in the hopes that it will aid oncology researchers worldwide in better understanding cancer genetics and improving treatment regimens.
For more information see the original post in Drug Discovery News